Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Efgartigimod Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT07673744
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Ublituximab, Placebo
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Farmington Hills, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Efgartigimod in Patients With IgG4-Related Disease

NCT07025330
View directory record Official record
Conditions
IgG4-related Disease
Interventions
Efgartigimod
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279
View directory record Official record
Conditions
Myasthenia Gravis, Ocular
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Scottsdale, Arizona • Loma Linda, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04687072
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
14
States / cities
Springdale, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

NCT03669588
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
25
States / cities
Phoenix, Arizona • Carlsbad, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

NCT04818671
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Carlsbad, California • Palo Alto, California • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

NCT06909214
View directory record Official record
Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
La Jolla, California • Rancho Mirage, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 2 Interventional

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

NCT06831058
View directory record Official record
Conditions
Immune-mediated Thrombotic Thrombocytopenic Purpura
Interventions
efgartigimod
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

NCT02965573
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
ARGX-113, Placebo
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Irvine, California • Los Angeles, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

NCT03770403
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
ARGX-113
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Carlsbad, California • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting No phase listed Observational

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170
View directory record Official record
Conditions
Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions
Efgartigimod IV, Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
2 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04281472
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Interventions
efgartigimod PH20 SC in stage B, placebo in stage B
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 27, 2026, 4:52 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

NCT04598477
View directory record Official record
Conditions
Pemphigus Vulgaris, Pemphigus Foliaceus
Interventions
efgartigimod PH20 SC, prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 27, 2026, 4:52 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05918978
View directory record Official record
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 27, 2026, 4:52 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

NCT04735432
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
efgartigimod PH20 SC, efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

NCT07570316
View directory record Official record
Conditions
Graves' Disease, Graves Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
21
States / cities
Orange, California • Pasadena, California • Fleming Island, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04188379
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 27, 2026, 4:52 AM EDT
Terminated Phase 3 Interventional

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

NCT06307613
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

NCT06655155
View directory record Official record
Conditions
Systemic Sclerosis (SSc)
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847
View directory record Official record
Conditions
Primary Sjogrens Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
42
States / cities
Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 27, 2026, 4:52 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Targeting Collagen VII Antibodies in Bullous Diseases Using Efgartigimod IV (VYVGART)

NCT07011589
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Acquisita, Recessive Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
Efgartigimod
Biological
Lead sponsor
M. Peter Marinkovich
Other
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 27, 2026, 4:52 AM EDT